Solu, a Helsinki, Finland-based biotechnology company focusing on combating antibiotic resistance, raised €1M in funding.
The round was led by Lifeline Ventures with participation from Wave Ventures.
The company intends to use the funds to expand operations and its business reach.
Founded in 2022 by Sam Sihvonen, Kerkko Visuri, and Timo Moilanen, Solu is building a bacterial DNA database, allowing for the analysis, monitoring, and control of antibiotic-resistant bacteria. Its software makes it easier to understand, detect, and prevent the spread of antibiotic resistance and enables the development of new treatment methods against resistant bacteria.
As part of product development, the company has started collaborating with top international universities, including Stanford University and the University of Hamburg, which use its product in their research on antibiotic resistance.
In the future, Solu aims to build a pathogen DNA library that collects all pathogen data in real-time and can also model their evolution and identify new health-threatening pathogens more effectively.
FinSMEs
15/06/2023